结直肠癌联合靶向治疗中贝伐单抗影响CD151基因表达 的实验研究-外科学专业论文.docxVIP

万方数据 万方数据 目 录 中文摘要·····································································································1 英文摘要············································································································4 英文缩写·······································································································7 研究论文 贝伐单抗治疗结直肠癌中 CD151 基因表达的实验研究 前言········································································································8 材料与方法························································································10 结果··································································································17 附图·································································································19 附表·····································································································22 讨论······································································································23 结论···································································································26 参考文献····························································································27 综述 转移性结直肠癌（mCRC）靶向治疗进展···········································28 致谢···································································································47 个人简历·······························································································48 1 中 中 文 摘 要 PAGE 1万方数据 PAGE 1 万方数据 结直肠癌联合靶向治疗中贝伐单抗影响 CD151 基因表达的 实验研究 摘 要 目的：本实验旨在研究结肠癌接受常规化疗和联合抗 VEGF 靶向药 物治疗后，对比观察肿瘤组织中 CD151 蛋白的表达情况情况对微血管生 长的影响，探讨在结肠癌化疗中 CD151 蛋白的表达影响肿瘤血管生成的 作用机制。 方法： 1、人结肠癌细胞株 HT29 由河北中医学院药理实验室张伟老师惠赠， 45 只 BALB/c -nu/nu 雄性裸鼠，购自河北医科大学动物中心，将实验动物 随机分成对照组（A 组），化疗治疗组（B 组）和化疗联合靶向药物治疗 组（C 组）。各组存活裸鼠形成可见瘤体后，于起始日日晨分别向 A 组 裸鼠灌喂生理盐水，根据体重向 B、C 组按每克体重 0.3mg 给予裸鼠灌喂 30mg/ml 的卡培他滨生理盐水溶液，灌喂卡培他滨当日同样按每克体重 0.01mg 向 C 组实验裸鼠腹膜腔内注射 5mg/ml 的贝伐单抗溶液。 2、通过 Western blot 方法分别检测各组移植瘤组织中 CD151 蛋白的 表达情况。 3、通过免疫组化的方法使